| Kyle Cyr, MD | |
|
900 23rd St Nw, Washington, DC 20037-2342 | |
| (202) 157-4750 | |
| Not Available |
| Full Name | Kyle Cyr |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Location | 900 23rd St Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508256470 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | D0090105 (Maryland) | Secondary |
| 207L00000X | Anesthesiology | MD048894 (District Of Columbia) | Primary |
| Entity Name | North American Partners In Anesthesia Maryland Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093707879 PECOS PAC ID: 1850283144 Enrollment ID: O20040330000405 |
News Archive
In related coverage, religious colleges involved in a separate challenge to birth control mandate will go to court this week to argue their standing to bring a lawsuit.
It's no secret that studies show that sexually diverse youth - in particular, lesbian, gay and bisexual (LGB) youth - use more cannabis and experience more mental health challenges than their heterosexual peers.
Delcath Systems, Inc. has announced that the first fifty percent (46 of 92) of patients have been enrolled in the Phase III clinical trial treating metastatic cutaneous and ocular melanoma to the liver.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference, and miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA -based therapeutics for cardiovascular and muscle disease, announced today that they have entered into a research collaboration.
› Verified 9 days ago
| Entity Name | Lifebridge Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003992868 PECOS PAC ID: 2062514888 Enrollment ID: O20230627000605 |
News Archive
In related coverage, religious colleges involved in a separate challenge to birth control mandate will go to court this week to argue their standing to bring a lawsuit.
It's no secret that studies show that sexually diverse youth - in particular, lesbian, gay and bisexual (LGB) youth - use more cannabis and experience more mental health challenges than their heterosexual peers.
Delcath Systems, Inc. has announced that the first fifty percent (46 of 92) of patients have been enrolled in the Phase III clinical trial treating metastatic cutaneous and ocular melanoma to the liver.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference, and miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA -based therapeutics for cardiovascular and muscle disease, announced today that they have entered into a research collaboration.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kyle Cyr, MD 8901 Rockville Pike, Bethesda, MD 20889-0001 Ph: (301) 400-2120 | Kyle Cyr, MD 900 23rd St Nw, Washington, DC 20037-2342 Ph: (202) 157-4750 |
News Archive
In related coverage, religious colleges involved in a separate challenge to birth control mandate will go to court this week to argue their standing to bring a lawsuit.
It's no secret that studies show that sexually diverse youth - in particular, lesbian, gay and bisexual (LGB) youth - use more cannabis and experience more mental health challenges than their heterosexual peers.
Delcath Systems, Inc. has announced that the first fifty percent (46 of 92) of patients have been enrolled in the Phase III clinical trial treating metastatic cutaneous and ocular melanoma to the liver.
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference, and miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA -based therapeutics for cardiovascular and muscle disease, announced today that they have entered into a research collaboration.
› Verified 9 days ago
Dr. Fay Horng, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7504 | |
Dr. Matthew Mueller, DO, MPH Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7000 | |
Dr. Shane Zamani, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 900 23rd St Nw, Washington, DC 20037 Phone: 202-715-4750 | |
Dr. Thomas Edward Borsari, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 50 Irving St Nw, Dept Of Anesthesiology, Washington, DC 20422 Phone: 202-745-8000 | |
Alexis Lambros, CAA Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-2025 | |
Susan Verghese, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-884-2025 | |
Joan Threlfall, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Washington, DC 20007 Phone: 202-444-8640 |